AmpliPhi to Present at Upcoming Healthcare Conferences

Cowen and Company 34th Annual Healthcare Conference
26th Annual ROTH Conference

RICHMOND, Va. & COLWORTH, United Kingdom & SYDNEY--()--AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34th Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston at 2:50 pm EST (11:50 am PST) on Monday, March 3, 2014.

AmpliPhi will also be presenting at the 26th Annual ROTH Conference at the Ritz-Carlton in Laguna Niguel, CA at 4:30 pm EST (1:30 pm PST) on Monday, March 10, 2014.

Both presentations will be webcast and can be accessed via the Investor Relations page of the AmpliPhi website at www.ampliphibio.com. A recording of each webcast will be archived for 90 days on the company’s website.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (OTCBB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release about the potential use of bacteriophages to treat bacterial infections and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency.

Contacts

Investor and Media Contact:
AmpliPhi BioSciences Corporation
Baxter Phillips III, +1-804-754-5442
Vice President, Corporate Strategy and Business Development
bfp@ampliphibio.com

Release Summary

AmpliPhi, developing bacteriophage-based antibacterial therapies to treat drug resistant infections in C.F., MRSA and C. difficile infections, will present lead programs to healthcare conferences.

Sharing

Contacts

Investor and Media Contact:
AmpliPhi BioSciences Corporation
Baxter Phillips III, +1-804-754-5442
Vice President, Corporate Strategy and Business Development
bfp@ampliphibio.com